Latest News on Pfizer Inc. (PFE) Stock

  • Pfizer Is A Solid Buy In 2017 [February 19 2017 09:48 PM]
  • Pfizer Is A Solid Buy In 2017   Seeking Alpha - 5 hours ago Besides having a solid and well-diversified drug portfolio, Pfizer also boasts of having some of the most promising investigational therapies in its research pipeline. Read more about this Pfizer Inc. (PFE) news
  • Pfizer Near A Technical Breakout [February 18 2017 03:15 PM]
  • Pfizer Near A Technical Breakout   Seeking Alpha - Feb 18, 2017 Pfizer's share price won't go to the moon but I believe there is strong downside protection here mainly due to the company's sheer size and diversification. I think what dividend investors need to take into account here is that there are companies ... Pfizer Inc. (PFE) Closes Flat on the Day for February 17 - Equit... Read more about this Pfizer Inc. (PFE) news


  • Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc. [February 18 2017 08:41 AM]
  • Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc.   Madison.com - Feb 18, 2017 Pfizer's prospects have improved for several reasons. Several products in the company's current lineup are performing exceptionally well. The PGGM Investments Has $112552000 Position in Gilead Sciences, Inc. (GILD) - DailyQuint  Read more about this Pfizer Inc. (PFE) news


  • Pfizer Inc.: Invest For Attractive Valuation And The 4% Dividend Yield [February 9 2017 11:16 AM]
  • Pfizer Inc.: Invest For Attractive Valuation And The 4% Dividend Yield   Seeking Alpha - Feb 9, 2017 Pfizer Inc. (NYSE:PFE) is one of the world's largest pharmaceutical firms with sales exceeding $50 billion. The company is currently attractively valued at a blended P/E ratio of 13.3, offering a current dividend yield of 4%. Read more about this Pfizer Inc. (PFE) news
  • Roche says Phase II trial supports twin treatment for kidney cancer [February 18 2017 02:53 AM]
  • [Reuters] - Swiss pharmaceuticals company Roche said on Saturday that a combination of its immunotherapy drug Tecentriq and its blockbuster cancer drug Avastin had shown encouraging results in a Phase II trial in treating a type of kidney cancer. The study found that the combination had a "manageable safety profile" when used for locally advanced or metastatic renal cell carcinoma (mRCC). The test... Read more about this Pfizer Inc. (PFE) news

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center